138 results
8-K
EX-99.1
FGEN
FibroGen Inc
6 May 24
FibroGen Reports First Quarter 2024 Financial Results
4:05pm
www.fibrogen.com. www.fibrogen.com.
Forward-Looking Statements
This release contains forward-looking statements regarding FibroGen’s strategy, future plans
8-K
EX-99.1
FGEN
FibroGen Inc
26 Feb 24
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding the development
8-K
EX-99.1
z5ro lzy5vln5
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
4a77vo2swl39f5b5
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
EX-99.1
5qwg8vms2okp5j0
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
lzt lejzzn7
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
8qn59nuq3p qn9smm
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
n9bv9koeq vy
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
EX-99.1
tuwxi3j14s
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
e6keg1hxk5ckh
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
EX-99.1
9othx i974xdl
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am
8-K
EX-99.1
a29ai
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm